Library to enable esp32-based devices to interact with Bitfocus Companion as surfaces via the Satellite API - elliotmatson/companion-microsatellite

Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted th…

After the recent Starlink slowdown, Ukraine is being forced to build redundancy and alternatives.

The phase III CheckMate 8HW trial met its dual primary endpoints of superior progression-free survival (PFS) with nivolumab plus ipilimumab (NIVO + IPI) versus chemotherapy [first-line (1L)] and versu...

The accelerated approval of dostarlimab (Jemperli) could allow eligible patients with biomarker-defined rectal cancer to avoid chemotherapy, radiotherapy, and surgery.

We profiled 54 EO-CRC and 135 AO-CRC primary tumor samples from banked frozen resection specimens using 3′ snRNA-seq (Fig. 1a), with >20 samples in most age decades (Fig. 1b). Tumors were annotated for patient sex, primary tumor sidedness, microsatellite status, neoadjuvant treatment history, stage and Lynch syndrome status (Fig. 1c and Supplementary Table 1). Consistent with prior reports9,12, tumor sidedness and stage were significantly associated with age in our cohort (chi-square test, two-sided; sidedness: χ2 = 19.3, degrees of freedom = 2, false discovery rate (FDR) = 0.00032; stage: χ2 = 13.0, degrees of freedom = 3, FDR = 0.016), with more left-sided tumors (Fisher’s exact test, two-sided; odds ratio (OR) 3.61, 95% confidence interval (CI) 1.85–7.04, P = 0.0002) and stage IV tumors (OR 2.55, 95% CI 1.23–5.27, P = 0.017) in EO-CRC compared to AO-CRC. There was no significant association between age and sex, microsatellite status or neoadjuvant treatment history in our cohort. From the 189 patient tumor samples, we assembled an snRNA-seq CRC atlas of 850,222 high-quality nuclei (median per sample: 1,582 genes, 2,408 unique molecular identifiers (UMIs), 4,483 nuclei, 0.25% mitochondrial UMIs; Extended Data Fig. 1a and Supplementary Table 1). We identified seven cell lineages: epithelial...

Adagene (ADAG) announced first-patient dosing in a Phase 1 study combining muzastotug with Incyte’s INCA33890 for microsatellite stable colorectal cancer.The open-label trial, in which treatment is known, includes dose escalation and expansion in third-line patients whose cancer progressed on prior therapies, with or without liver metastases, meaning cancer spread to the liver. Incyte is sponsoring and conducting the study, while Adagene supplies muzastotug under the collaboration announced in April 2026. Adagene said the study will evaluate whether the combination can deepen and sustain antitumor responses with an acceptable safety profile.

Read the full paper: Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities

We profiled 54 EO-CRC and 135 AO-CRC primary tumor samples from banked frozen resection specimens using 3′ snRNA-seq (Fig. 1a), with >20 samples in most age decades (Fig. 1b). Tumors were annotated for patient sex, primary tumor sidedness, microsatellite status, neoadjuvant treatment history, stage and Lynch syndrome status (Fig. 1c and Supplementary Table 1). Consistent with prior reports9,12, tumor sidedness and stage were significantly associated with age in our cohort (chi-square test, two-sided; sidedness: χ2 = 19.3, degrees of freedom = 2, false discovery rate (FDR) = 0.00032; stage: χ2 = 13.0, degrees of freedom = 3, FDR = 0.016), with more left-sided tumors (Fisher’s exact test, two-sided; odds ratio (OR) 3.61, 95% confidence interval (CI) 1.85–7.04, P = 0.0002) and stage IV tumors (OR 2.55, 95% CI 1.23–5.27, P = 0.017) in EO-CRC compared to AO-CRC. There was no significant association between age and sex, microsatellite status or neoadjuvant treatment history in our cohort. From the 189 patient tumor samples, we assembled an snRNA-seq CRC atlas of 850,222 high-quality nuclei (median per sample: 1,582 genes, 2,408 unique molecular identifiers (UMIs), 4,483 nuclei, 0.25% mitochondrial UMIs; Extended Data Fig. 1a and Supplementary Table 1). We identified seven cell lineages: epithelial...

Sadanandam et al. integrate multiomic, single-cell, and clinical data from ∼2,000 CRC tumors (∼4,500 multiomic profiles including 195,246 cells/nuclei) to define microsatellite stable (MSS) CRC complexity. Analyses identify replication stress, right-sidedness, glutaminolysis, and MYC-E2F-associated epigenetic programs as key features and FAK, PDK1/2, and proteasomal inhibition, combined with trametinib, as potential therapeutic strategies in MSS CRC.

In this issue of Cancer Cell, Sadanandam et al. integrate multi-omics profiling of microsatellite-stable colorectal cancer with patient-derived models, identifying focal adhesion kinase and phosphoinositide-dependent kinase 1 as promising therapeutic targets. The study advances multi-omics discoveries toward functional precision oncology and potential treatment strategies to guide clinical translation.

COLOSSUS Team IDs Multiomic Features, Treatment Targets in Microsatellite-Stable Colorectal Cancer

Major new research published today identifies potential new ways to treat the most common type of bowel cancer in Ireland. More ...

Jiang et al. show that Akkermansia muciniphila reshapes the tumor immune environment to overcome PD-1 resistance in microsatellite-stable colorectal cancer (MSS CRC). Mechanistic studies and a phase 1...

Paul E. Oberstein, MD, discusses the rationale for the anti-PD-1/IL-15 fusion protein SAR445877 in microsatellite-stable colorectal cancer.